Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDUM0Z)

Drug Name
LymphoRad-131 Drug Info
Synonyms Ardenermin; LymphoRad; LR-131; Radiolabeled BLyS protein, HGS; Radiolabeled ardenermine, HGS
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Discontinued in Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMDUM0Z

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting B-cell-activating factor (TNFSF13B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Belimumab DM3OBQF Membranous glomerulonephritis Approved [3]
Blisibimod DM7V9LH Systemic lupus erythematosus 4A40.0 Phase 3 [4]
Tabalumab DMKSAG1 Multiple myeloma 2A83 Phase 3 [5]
AMG 570 DMY1XJH Systemic lupus erythematosus 4A40.0 Phase 2 [6]
BR3-Fc DMFN1WI Idiopathic thrombocytopenic purpura 3B64.10 Discontinued in Phase 2 [7]
Receptor-Fc fusion proteins DM4B6FO Discovery agent N.A. Investigative [8]
1,4-Diethylene Dioxide DMI36WC Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell-activating factor (TNFSF13B) TTWMIDN TN13B_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016875)
2 Fusion Toxin BLyS-Gelonin Inhibits Growth of Malignant Human B Cell Lines In Vitro and In Vivo. PLoS One. 2012; 7(10): e47361.
3 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann Rheum Dis. 2013 Sep 1;72(9):1461-8.
6 Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment. Clin Exp Rheumatol. Nov-Dec 2019;37(6):906-914.
7 Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
8 BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders. Expert Opin Ther Targets. 2003 Feb;7(1):115-23.
9 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.